Skip to main content

Table 1 CHIPS trial event rates of the seven outcomes women prioritized, overall and by trial arma

From: Using a patient-centred composite endpoint in a secondary analysis of the Control of Hypertension in Pregnancy Study (CHIPS) Trial

Outcome (presence of)

Outcome data from CHIPS trial [4]

Weights from preference study [11]

Overall (N = 981)

Trial arm

Equal weights

Subgroups based on patient preference weightsb

‘Less-tight’ control (N = 493)

‘Tight' control (N = 488)

(1) (N = 114)

(2) (N = 44)

(3) (N = 25)

Prescribed antihypertensives

837 (85.3%)

379 (76.9%)c

458 (93.9%)c

14%

14%

2%

58%

Severe hypertension

334 (34.0%)

200 (40.6%)c

134 (27.5%)c

14%

11%

20%

20%

Pre-eclampsia

464 (47.3%)

241 (48.9%)

223 (45.7%)

14%

15%

16%

10%

Blood transfusion

24 (2.4%)

16 (3.2%)

8 (1.6%)

14%

20%

2%

0%

Caesarean

481 (49.0%)

231 (47.0%)

250 (51.4%)

14%

13%

2%

4%

Delivery < 34 weeks

138 (14.1%)

77 (15.7%)

61 (12.6%)

14%

18%

42%

2%

BW < 10th percentile

175 (17.8%)

79 (16.1%)

96 (19.8%)

14%

8%

16%

5%

  1. BW birthweight
  2. aOf the 987 women randomized in CHIPS, outcomes were available for 981 following 6 withdrawals and losses to follow-up, with the exception of antihypertensive medication for which data were available for 986 women [4]
  3. bSubgroups (1) ‘equal prioritizers’, (2) ‘early delivery avoiders’, and (3) ‘medication minimizers’ [11]
  4. cThe difference between the groups was statistically significant at the p < 0.001 level
Back to article page

Trials

ISSN: 1745-6215